Emend (fosaprepitant) — CareFirst (Caremark)
Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy
Initial criteria
- Authorization may be granted when the requested drug is being prescribed for the prevention of nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy when ALL of the following criteria are met:
- • The request is NOT for Varubi (rolapitant).
- • The requested drug will be used in combination with other antiemetic agents.
- Authorization may be granted when the requested drug is being prescribed for the prevention of postoperative nausea and vomiting when the following criterion is met:
- • The request is for aprepitant capsules.
Approval duration
6 months